

**TDMS No.** 20201 - 01  
**Test Type:** 26-WEEK  
**Route:** SKIN APPLICATION  
**Species/Strain:** MICE/TG.AC HEMI

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
TEF TRANSGENICS (TCDD)  
**CAS Number:** 1746-01-6

**Date Report Reqsted:** 06/14/2006  
**Time Report Reqsted:** 13:12:56  
**First Dose M/F:** NA / 04/21/03  
**Lab:** BAT

**C Number:** C20201A

**Lock Date:** 07/24/2004

**Cage Range:** ALL

**Date Range:** ALL

**Reasons For Removal:** ALL

**Removal Date Range:** ALL

**Treatment Groups:** Include 001 0 NG/KG

Include 002 121 NG/KG

Include 003 760 NG/KG

TDMS No. 20201 - 01  
Test Type: 26-WEEK  
Route: SKIN APPLICATION  
Species/Strain: MICE/TG.AC HEMI

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
TEF TRANSGENICS (TCDD)  
CAS Number: 1746-01-6

Date Report Requested: 06/14/2006  
Time Report Requested: 13:12:56  
First Dose M/F: NA / 04/21/03  
Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	121 NG/KG	760 NG/KG
<b>Disposition Summary</b>			
Animals Initially in Study	20	20	20
Early Deaths			
Moribund Sacrifice	1	6	8
Natural Death	2	2	1
Survivors			
Terminal Sacrifice	17	12	11
Animals Examined Microscopically	20	20	20
<b>ALIMENTARY SYSTEM</b>			
Liver	(20)	(20)	(20)
Clear Cell Focus	1 (5%)		
Fatty Change	1 (5%)	4 (20%)	8 (40%)
Hematopoietic Cell Proliferation	1 (5%)	4 (20%)	7 (35%)
Hepatodiaphragmatic Nodule	1 (5%)		
Inflammation	19 (95%)	19 (95%)	18 (90%)
Myelodysplasia			2 (10%)
Necrosis	7 (35%)	9 (45%)	13 (65%)
Pigmentation	10 (50%)	9 (45%)	15 (75%)
Tension Lipidosis			1 (5%)
Centrilobular, Vacuolization Cytoplasmic			1 (5%)
Hepatocyte, Degeneration			4 (20%)
Mesentery	(1)	(0)	(1)
Fat, Necrosis	1 (100%)		1 (100%)
Salivary Glands	(1)	(0)	(0)
Stomach, Forestomach	(6)	(4)	(5)
Hyperplasia			2 (40%)
Stomach, Glandular	(1)	(0)	(1)
Glands, Hyperplasia	1 (100%)		1 (100%)
Tooth	(6)	(6)	(2)
Malformation		1 (17%)	
<b>CARDIOVASCULAR SYSTEM</b>			
Heart	(0)	(1)	(1)
Inflammation, Chronic Active			1 (100%)

TDMS No. 20201 - 01  
 Test Type: 26-WEEK  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/TG.AC HEMI

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 TEF TRANSGENICS (TCDD)  
 CAS Number: 1746-01-6

Date Report Requested: 06/14/2006  
 Time Report Requested: 13:12:56  
 First Dose M/F: NA / 04/21/03  
 Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	121 NG/KG	760 NG/KG
Thrombosis		1 (100%)	1 (100%)
ENDOCRINE SYSTEM			
None			
GENERAL BODY SYSTEM			
None			
GENITAL SYSTEM			
None			
HEMATOPOIETIC SYSTEM			
Lymph Node	(0)	(0)	(1)
Lymph Node, Mandibular	(0)	(1)	(2)
Hyperplasia, Lymphoid		1 (100%)	2 (100%)
Spleen	(20)	(20)	(20)
Hematopoietic Cell Proliferation	3 (15%)	9 (45%)	11 (55%)
Myelodysplasia			2 (10%)
Thymus	(20)	(19)	(19)
Atrophy	3 (15%)	3 (16%)	5 (26%)
INTEGUMENTARY SYSTEM			
Skin	(4)	(2)	(6)
Cyst Epithelial Inclusion			1 (17%)
Fibrosis	1 (25%)		
Hyperplasia, Squamous	4 (100%)		
Inflammation, Chronic Active	3 (75%)	1 (50%)	4 (67%)
Ulcer	1 (25%)		
Skin, Control Dermis	(20)	(20)	(20)
Inflammation, Chronic Active			4 (20%)
Skin, Control Epidermis	(20)	(20)	(20)
Hyperkeratosis		1 (5%)	
Hyperplasia, Squamous		1 (5%)	

TDMS No. 20201 - 01

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: MICE/TG.AC HEMI

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

TEF TRANSGENICS (TCDD)

CAS Number: 1746-01-6

Date Report Requested: 06/14/2006

Time Report Requested: 13:12:56

First Dose M/F: NA / 04/21/03

Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	121 NG/KG	760 NG/KG
Skin, Site Of Application	(20)	(20)	(20)
Fibrosis	1 (5%)	1 (5%)	
Hyperkeratosis			1 (5%)
Hyperplasia, Squamous	1 (5%)	13 (65%)	14 (70%)
Inflammation, Chronic Active	2 (10%)	17 (85%)	20 (100%)
Skin, Soa No Mass	(20)	(20)	(17)
Hyperplasia, Mast Cell		1 (5%)	
Hyperplasia, Squamous	1 (5%)	6 (30%)	10 (59%)
Inflammation, Granulomatous			1 (6%)
Inflammation, Chronic Active	3 (15%)	8 (40%)	13 (76%)
Ulcer		1 (5%)	
MUSCULOSKELETAL SYSTEM			
None			
NERVOUS SYSTEM			
None			
RESPIRATORY SYSTEM			
Lung	(20)	(20)	(20)
Alveolar Epithelium, Hyperplasia			1 (5%)
Alveolus, Infiltration Cellular, Histiocyte		2 (10%)	1 (5%)
Bronchiole, Inflammation			2 (10%)
Interstitial, Inflammation	1 (5%)	1 (5%)	3 (15%)
Perivascular, Infiltration Cellular, Mixed Cell		1 (5%)	
Perivascular, Inflammation	2 (10%)	2 (10%)	2 (10%)
Serosa, Inflammation, Chronic Active	7 (35%)	4 (20%)	4 (20%)
SPECIAL SENSES SYSTEM			
None			
URINARY SYSTEM			
Kidney	(0)	(0)	(2)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20201 - 01  
Test Type: 26-WEEK  
Route: SKIN APPLICATION  
Species/Strain: MICE/TG.AC HEMI

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
TEF TRANSGENICS (TCDD)  
CAS Number: 1746-01-6

Date Report Reqsted: 06/14/2006  
Time Report Reqsted: 13:12:56  
First Dose M/F: NA / 04/21/03  
Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	121 NG/KG	760 NG/KG
Renal Tubule, Dilatation			1 (50%)
Renal Tubule, Vacuolization Cytoplasmic			1 (50%)

\*\*\* END OF REPORT \*\*\*